Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +25.33% | +28.26% | +43.56% | +19.44% | +15.31% |
| Gross Profit Growth | +23.61% | +26.82% | +43.63% | +8.67% | +12.49% |
| EBITDA Growth | +0.00% | +42.23% | +99.22% | +23.67% | +58.03% |
| Operating Income Growth | +0.00% | +50.73% | +133.60% | +22.22% | +30.17% |
| Net Income Growth | +0.00% | +60.53% | +143.77% | +27.73% | +20.28% |
| EPS Growth | +0.00% | +42.42% | +135.00% | +22.86% | +16.22% |
| EPS Diluted Growth | +0.00% | +41.94% | +136.84% | +24.24% | +20.00% |
| Weighted Average Shares Growth | +11.60% | +12.35% | +3.99% | +3.37% | +3.09% |
| Weighted Average Shares Diluted Growth | +17.68% | +11.01% | +2.88% | +2.32% | +1.34% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +61.48% | +27.37% | +88.08% | +11.17% | -55.49% |
| Free Cash Flow Growth | +61.13% | +32.74% | +89.25% | +11.15% | -55.33% |
| Receivables Growth | +21.26% | +22.06% | +19.17% | +15.77% | +83.24% |
| Inventory Growth | +121.55% | +24.91% | -0.88% | +3.53% | +40.03% |
| Asset Growth | +86.83% | +81.11% | +40.55% | +37.59% | +36.22% |
| Book Value per Share Growth | +69.92% | +66.97% | +36.05% | +36.06% | +35.06% |
| Debt Growth | -9.91% | -10.37% | -10.87% | -11.40% | -11.97% |
| R&D Expense Growth | -96.07% | +92.60% | +50.60% | +46.00% | -19.09% |
| SG&A Expenses Growth | +36.71% | +5.13% | -0.06% | +12.81% | +3.47% |